Document is current
Any future updates will be listed below
-
Authors
Yoshifuji, Ayumi https://orcid.org/0000-0001-8246-8675
Toda, Masataro
Oyama, Emi
Nakayama, Tetsuo
Mise-Omata, Setsuko
Kikuchi, Kan
Yoshizawa, Mamoru
Kato, Naohiko
Wakai, Haruki
Koibuchi, Kiyoto
Morimoto, Kohkichi
Uwamino, Yoshifumi
Namkoong, Ho
Shibata, Ayako
Wakabayashi, Kaoru
Fujino, Motoko
Komatsu, Motoaki
Mochizuki, Naoki
Kondo, Norihiko
Yoshimura, Akihiko
Hasegawa, Naoki
Ryuzaki, Munekazu
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP22gm1110009, JP22zf0127003, JP20fk0108415, JP20fk0108452, JP21fk0108469, JP21fk0108468, JP21ym0126022, JP20fk0108283, 21fk0108469h0001)
Japan Society for the Promotion of Science (21H05044, 22K1944)
- License Information
-
More Information
Article History
Received: 3 July 2023
Accepted: 13 February 2024
First Online: 8 March 2024
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yoshifumi Uwamino reports that equipment and supplies for the measurement of QuantiFERON were provided by QIAGEN GmbH.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of Tokyo Saiseikai Central Hospital Clinical at which the studies were conducted (IRB approval number 2021-029) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This prospective multicenter study was approved by the Ethics Committee of Tokyo Saiseikai Central Hospital (approval numbers 2021-029).
: Written content was obtained from all the participants for this study.
